Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine

Tong Zhang; Wen-ting He; Ming-jie Zi; Gang Song; Dan-hui Yi; Yu-fei Yang

doi:10.1007/s11655-018-2980-0

Your Location：

Home >

Browse articles >

Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine

Updated：2021-08-27

- Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine
- Chinese Journal of Integrative Medicine Vol. 24, Issue 8, Pages: 573-578(2018)
- Affiliations：
  
  1. Department of Oncology, Xiyuan Hospital of China Academy of Chinese Medicial Sciences,Beijing,China
  2. Second Department of Oncology, Traditional Chinese Medicine, Hospital Affiliated to Xinjiang Medical University,Urumchi,China
  3. Ethics Committee, Xiyuan Hospital of China Academy of Chinese Medicial Sciences,Beijing,China
  4. Department of Digestive Oncology, Beijing Cancer Hospital,Beijing,China
  5. School of Statistics, Renmin University of China,Beijing,China
- Author bio：
- Funds：
  
  Supported by National Natural Science Foundation of China (No. 81373824), Beijing Health Development Research Project (No. 2016-1-4147), Project of the Chinese Academy of Traditional Chinese Medicine (No. ZZ070854)
- DOI：10.1007/s11655-018-2980-0
  CLC：
- Published：2018，
  
  Published Online：22 May 2018，
Scan for full text
Zhang, T., He, Wt., Zi, Mj. et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine., Chin. J. Integr. Med. 24, 573–578 (2018). https://doi.org/10.1007/s11655-018-2980-0

Tong Zhang, Wen-ting He, Ming-jie Zi, et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine. [J]. Chinese Journal of Integrative Medicine 24(8):573-578(2018)
Zhang, T., He, Wt., Zi, Mj. et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine., Chin. J. Integr. Med. 24, 573–578 (2018). https://doi.org/10.1007/s11655-018-2980-0 DOI：

Tong Zhang, Wen-ting He, Ming-jie Zi, et al. Cohort Study on Prognosis of Patients with Metastatic Colorectal Cancer Treated with Integrated Chinese and Western Medicine. [J]. Chinese Journal of Integrative Medicine 24(8):573-578(2018) DOI： 10.1007/s11655-018-2980-0.

摘要

To investigate the efficacy of integrated Chinese and Western medicine (IM) in the treatment of metastatic colorectal cancer (mCRC) in a cohort study. The survival outcome of patients receiving IM was compared with that of patients receiving Western medicine alone. The study design was adopted with “continuous administration of Chinese medicine for ⩾ 3 months” as the exposure factor. Patients who met this exposure factor were assigned to the IM cohort (Group A

110 patients). Patients who did not meet this exposure factor were assigned to the Western medicine cohort (Group B

225 patients). The overall survival (OS)

progression-free survival (PFS)

and 1st year

2nd year

and 3rd year survival in the two cohorts were compared. The median OS in Group A and B were 18 months [95% confidence interval (CI) 15–21] and 16 months (95% CI 14–18)

respectively

and the median PFS in Group A and B were 6 months (95% CI 4–7) and 5 months (95% CI 4–6)

respectively. No statistically significant differences were observed between the groups (P=0.186

P=0.223). Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups: female patients

patients with lesions in the right half of the colon

and those who received first-line treatment (P<0.05). In the subgroup of elderly patients (age>65 years)

the OS in Group A was longer than that in Group B (P<0.05). IM could prolong the survival of patients with mCRC. (Registry No. ChiCTR-IOR-17010497)

Abstract

110 patients). Patients who did not meet this exposure factor were assigned to the Western medicine cohort (Group B

225 patients). The overall survival (OS)

progression-free survival (PFS)

and 1st year

2nd year

and 3rd year survival in the two cohorts were compared. The median OS in Group A and B were 18 months [95% confidence interval (CI) 15–21] and 16 months (95% CI 14–18)

respectively

and the median PFS in Group A and B were 6 months (95% CI 4–7) and 5 months (95% CI 4–6)

respectively. No statistically significant differences were observed between the groups (P=0.186

P=0.223). Group A demonstrated significantly longer OS and PFS than Group B in the following subgroups: female patients

patients with lesions in the right half of the colon

and those who received first-line treatment (P<0.05). In the subgroup of elderly patients (age>65 years)

the OS in Group A was longer than that in Group B (P<0.05). IM could prolong the survival of patients with mCRC. (Registry No. ChiCTR-IOR-17010497)

关键词

cohort studymetastatic colorectal cancerIntegrative Medicine

Keywords

cohort studymetastatic colorectal cancerIntegrative Medicine

references

Rebecca L, Siegel MPH, Kimberly D, Miller MPH, Ahmedin J, DVM PHD. Global cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.

Chen WQ, Zheng RS, Zeng HM, Zhang SW, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res (Chin) 2015;27:2–12.

Yang YF, Xu Y, Wu Y, Wang LP, Li Z, Zhang LZ, et al. Randomized controlled clinical study of Quxie Capsule in reducing postoperative relapse and metastasis of colorectal cancer. Chin J Integr Tradit Chin West Med (Chin) 2007;27:879–882.

Luo L, Yang YF, Li PH, Wu Y, Zhang JW, Wu XW, et al. Cohort study on Fuzheng Capsule and Quxie Capsule in reducing relapse and metastasis of cancer in patients with stage II and III colorectal carcinoma after operation. Chin J Integr Tradit Chin West Med (Chin) 2006;26:677–680.

Yang YF, Chen ZX, Xu Y, Wu Y, Wu XW, Zhu YW, et al. Randomized controlled study of Quxie Capsule in improving survival and quality of life of advanced colorectal cancer patients. Chin J Integr Tradit Chin West Med (Chin) 2008;28:111–113.

Zhang T, Yang YF, He B, Yi DH, Hao J, Zhang D. Efficacy and safety of Quxie Capsule in metastatic colorectal cancer: A double-blind, randomized, placebo controlled trial. Chin J Integr Med 2018;24:171–177.

Edge SB. American Joint Committee on Cancer: AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:2495–2501.

Shen HB, Qi XY, eds. Epidemiology. 8th ed. Beijing: People’s Medical Publishing House; 2013:54.

Castleberry AW, Güller U, Tarantino I, Berry MF, Brugger L, Warschkow R, et al. Discrete improvement in racial disparity in survival among patients with stage IV colorectal cancer: a 21-Year Population-Based Analysis. J Gastrointest Surg 2014;18:1194–1204.

Mik M, Berut M, Dziki L, Trzcinski R, Dziki A. Right- and leftsided colon cancer—clinical and pathological differences of the disease entity in one organ. Arch Med Sci 2017;13:157–162.

Petrelli F, Tomasello G, Borgonovo K, Ghidini M, Turati L, Dallera P, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and metaanalysis. JAMA Oncol 2016 Oct 27 [Epub ahead of print].

Tejpar S, Stintzing S, Ciardiello F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol 2016 Oct 10 [Epub ahead of print].

Li D, Fu Q, Li M, Li J, Yin C, Zhao J, et al. Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis. Future Oncol 2017;13:1115–1127.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Chinese medicine education and its challenges in the United States

Search of novel model for integrative medicine

Syndrome pattern and its application in parallel randomized controlled trials

The Western model of integrative oncology — the contribution of Chinese medicine

Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine

Related Author

No data

Related Institution

Acupuncture & Oriental Medicine Program, National University of Health Sciences, Lombard

Interdisciplinary School of Health Sciences, University of Pune, Pune

Former Director, WHO Liaison Office New York

Division of Clinical Medicine, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea

Department of Korean Medicine, School of Korean Medicine, Pusan National University, Yangsan, Republic of Korea

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰